Sertraline vs cognitive behavioural therapy
Adverse effects · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted1 study · 118 participantsLow
Findings
What do systematic reviews say?
4,783 questions · 10,022 findings · 882 reviews
No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
> 50% reduction in depressive symptoms · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Depressive symptoms · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Seizure frequency · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Treatment withdrawal · people with epilepsy and depression
It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).
1 finding from 1 review
- RR 0.44 [0.05, 3.85]15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Cognitive function · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted15 participantsVery low
Selective serotonin reuptake inhibitors vs cognitive behavioural therapy
Adverse effects ‐ adverse event profile · people with epilepsy and depression
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
Overall survival: Median length of · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 1.01 [0.98, 1.05]12 studies · 4325 participantsHigh
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
Disease-free survival · patients with early breast cancer
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 0.93 [0.86, 1.01]8 studies · 13547 participantsModerate
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
DFS: hormone receptor‐positivemedian · patients with early breast cancer
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 1.03 [0.91, 1.17]5 studies · 5604 participantsModerate
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
DFS: hormone receptor‐negativemedian · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 0.76 [0.65, 0.88]7 studies · 2879 participantsModerate
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
OS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 0.9 [0.8, 1.02]6 studies · 1565 participantsHigh
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
Overall survival: Median length of · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 0.89 [0.81, 0.98]8 studies · 13547 participantsModerate
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
Febrile neutropenia · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyOR 0.55 [0.47, 0.64]5 studies · 8086 participantsModerate
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
Diarrhoea · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyOR 2.46 [2.01, 3.01]8 studies · 11207 participantsModerate
Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy
Hand‐foot syndrome · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyOR 13.6 [10.65, 17.37]8 studies · 11207 participantsModerate
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
OS: hormone receptor‐negativemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 1.05 [0.91, 1.2]7 studies · 1408 participantsHigh
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
Progression‐free survival · people with metastatic breast cancer
Capecitabine‐containing regimens probably leads to lower progression‐free survival (PFS)median compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 0.89 [0.83, 0.96]12 studies · 4325 participantsModerate
Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
PFS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens probably leads to lower PFS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyHR 0.77 [0.68, 0.87]6 studies · 1372 participantsModerate